Rad Fan 20/6 2022年6月号

出版社: メディカルアイ
発行日: 2022-05-31
分野: 医療技術  >  雑誌
ISSN: 13483498
雑誌名:
特集: 1.乳癌最新TOPICS 2.JRC2022 HYBRID REPORT
電子書籍版: 2022-05-31
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

2,900 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,319 円(税込)

目次

  • 特集1 乳癌最新TOPICS CLINICAL REPORT
    特集2 JRC2022 HYBRID REPORT
        ~ミライの学会の在り方がわかる~

    特集1 乳癌最新TOPICS CLINICAL REPORT
     ●序文 
     ●超音波画像診断とAI
     ●マンモグラフィとAI活用 
     ●世界における造影マンモグラフィの現状と使いどころ 
     ●乳房専門PETガイドライン改訂と今後の展望 
     ●HBOCにおけるMRI detected lesionは2ndLookUSでここまで見える 
     ●乳癌罹患リスクに応じた効率的な乳癌検診
     ●乳癌学会とJABTSが共催で行う「乳房超音波基礎・針生検講習会」について
     ●術前化学療法の効果で変わる乳癌治療
     ●術前化学療法の効果判定 ~乳腺外科医の立場から~

    特集2 JRC2022 HYBRID REPORT
        ~ミライの学会の在り方がわかる~
     ITEM2022×online
     ITEM2022へのオンライン参加
     JRC/ITEM2022に参加してwithコロナ時代の学会参加
     JRC2022とITEM2022に参加して
     JRC2022からみる放射線治療の最新とこれから
     3年ぶりの現地参加を終えて/ITEM2022参加レポート
     Photon-counting CTがやってきた
     ITEM 2022参加レポート
     リフレクションのきっかけとなったJRC2022
     JRC2022 ハイブリット開催に参加して
     ITEMのすべてを解き明かす
     ITEM 2022参加レポート
     ハイブリッド参加で臨むJRC2022
     web参加で楽しむJRC2022~乳房画像診断に関わる内容を中心に~

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集1 乳癌最新TOPICS CLINICAL REPORT】

P.34 掲載の参考文献
1) K Simonyan et al:Very deep convolutional networks for large-scale image recognition. ICLR, 201
2) T Watanabe et al:Multicenter prospective study of color doppler ultrasound for breast masses:Utility of our color doppler method. Ultrasound in Med. & Biol 45(6):1367-1379, 2019
3) N Nishida et al:Artificial intelligence(AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. J. Gastroenterlogy 57(4):309-321, 2022
P.37 掲載の参考文献
1) Myers ER et al:Benefits and Harms of Breast Cancer Screening:A Systematic Review. JAMA 314(15):1615-34, 2015
2) Ohuchi N et al:Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START):a randomized controlled trial. Lancet 387(10016):341-348, 2016
3) Lehman CD et al:Diagnostic Accuracy of Digital Screening Mammography With and Without Computer-Aided Detection. JAMA Intern Med 175(11):1828-37, 2015
4) Fenton JJ et al:Influence of computeraided detection on performance of screening mammography. N Engl J Med 356(14):1399-409, 2007
5) Salim M et al:External evaluation of 3 commercial artificial intelligence algorithms for independent assessment of screening mammograms. JAMA Oncol 6:1581-1588, 2020
6) Freeman K et al:Use of artificial intelligence for image analysis in breast cancer screening programmes:systematic review of test accuracy. BMJ 374, n1872, 2020
7) Larsen M et al:Artificial Intelligence Evaluation of 122 969 Mammography Examinations from a Population-based Screening Program. Radiology 212381, 2022
8) Yamaguchi T et al:A deep learning-based automated diagnostic system for classifying mammographic lesions. Medicine 99(27):e20997, 2020
9) Balleyguier C et al:Improving digital breast tomosynthesis reading time:A pilot multi-reader, multi-case study using concurrent Computer-Aided Detection(CAD). Eur J Radiol 97:83-89, 2017
10) Pacile S et al:Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool. Radiology:Artificial Intelligence 2(6):e190208, 2020
11) Rodriguez-Ruiz A et al:Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study. European Radiology 29(9):4825-4832, 2019
12) Wolfe JN et al:Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 126(6):1130-7, 1976
13) Highnam R et al:Mammographic Image Analysis. Computational Imaging and Vision. Kluwer Academic, New York, NY, USA, 1999
14) van Engeland S et al:Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging (3):273-82, 2006
P.41 掲載の参考文献
1) Ghaderi KF et al:Contrast-enhanced mammography current applications and future directions. RadioGraphics 39(7):1907-1920, 2019
2) Jochelson MS et al:Contrast-enhanced mammography state of the art. Radiology 299(1):36-48, 2021
3) Lewin JM et al:Dual energy contrast enhanced digital mammography feasibility. Radiology 229:261-68, 2003
4) Cozzi A:Contrast-enhanced mammography a systematic review and meta-analysis of diagnostic performance. Radiology 302(3):568-581, 2022
5) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)). Breast Cancer Screening and Diagnosis. Version:1, 2021 https://www.nccn.org/guidelines/category_2
6) Contrast Enhanced Mammography Imaging Screening Trial (CMIST). American College of Radiology website. https://www.acr.org/Research/Clinical-Research/CMIST. Accessed November 1, 2021.
7) Neeter LMFH et al:Rapid Access to Contrast-Enhanced spectral mammogRaphy in women recalled from breast cancer screening:the RACER trial study design Trials 20(1):759, 2019
8) Contrast Enhanced Mammography (CEM)2022 (A supplement to ACR BI-RADS(R) Mammography 2013) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Bi-Rads
9) Zanardo M et al:Technique, protocols and adverse reactions for contrast-enhanced spectral mammography (CESM):a systematic review. Insights into Imaging 10(1), 2019
10) Patel BK et al:Potential cost savings of contrast-enhanced digital mammography. American Journal of Roentgenology 208(6):W231-W237, 2017
11) Yuen S et al:Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer:comparison with contrastenhanced breast MRI. Breast Cancer 2022 Feb 26. Online ahead of print.
12) Lee-Felker SA et al:Newly Diagnosed Breast Cancer:Comparison of Contrastenhanced Spectral Mammography and Breast MR Imaging in the Evaluation of Extent of Disease. Radiology. 285(2):389-400, 2017
13) Fallenberg EM et al:Contrast-enhanced spectral mammography vs. mammography and MRI-clinical performance in a multi-reader evaluation. Eur Radiol 27(7):2752-2764, 2017
14) Planning surgical treatment:contrastenhanced spectral mammography. European Commission website. https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/surgical-planning/CESM Updated October 29, 2021
P.45 掲載の参考文献
1) 日本乳癌学会:乳癌診療ガイドライン2018年版
2) Caglar M et al:Detection of bone metastases in breast cancer patients in the PET/CT era:Do we still need the bone scan? Rev Esp Med Nucl Imagen Mol 35(1):3-11, 2016
3) 日本核医学会:乳房専用PET診療ガイドライン, 2019 (修正2020年4月)
4) Satoh Y et al:Clinical practice guidelines for high-resolution breast PET, 2019 edition. Ann Nucl Med 35(3):406-414, 2021 Available from:http://dx.doi.org/10.1007/s12149-021-01582-y
5) Satoh Y et al:Unexpected Abnormal Uptake in the Breasts at Dedicated Breast PET:Incidentally Detected Small Cancers or Nonmalignant Features? AJR Am J Roentgenol 212(2):443-449, 2019
6) Yamamoto Y et al:A preliminary report of breast cancer screening by positron emission mammography. Ann Nucl Med 30(2):130-7, 2016
7) Sueoka S et al:Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer. Breast Cancer Res Treat 187(1):125-133, 2021 Available from:http://dx.doi.org/10.1007/s10549-020-06088-1
8) Berg WA et al:Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol 198(1):219-32, 2012
9) 公益財団法人日本対がん協会:各種の検診について/乳がんの検診について/検診の意義と目的. https://www.jcancer.jp/about_cancer_and_checkup/
10) Schilling K et al:Positron emission mammography in breast cancer presurgical planning:comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 38(1):23-36, 2011
11) Orsaria P et al:Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy:Impact on Breast Cancer Recurrence and Survival. Anticancer Res 41(5):2697-2709, 2021
12) von Minckwitz G et al:Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796-804, 2012
13) Koyasu H et al:The feasibility of dedicated breast PET for the assessment of residual tumor after neoadjuvant chemotherapy. Jpn J Radiol 37(1):81-7, 2019
14) Tokuda Y et al:Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer:comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI. Breast Cancer Res Treat 188(1):107-115, 2021 Available from:http://dx.doi.org/10.1007/s10549-021-06179-7
15) Miyake KK et al:A Proposed Dedicated Breast PET Lexicon:Standardization of Description and Reporting of Radiotracer Uptake in the Breast. Diagnostics (Basel) 11(7):1267, 2021 Available from:http://dx.doi.org/10.3390/diagnostics11071267
16) 日本核医学会・PET核医学委員会:18F-FDGを用いた全身PETのための標準的プロトコール, 2018.5.28
17) PET撮像法標準化ワーキンググループ:がんFDG PET/CT撮像法ガイドライン第2版. 核医学技術 33:377-420, 2013
18) がんFDG-PET撮像法の標準化ワーキンググループ:がんFDG-PET/CT撮像法ガイドライン ファントム試験マニュアル NEMA IECボディファントムの準備~撮像手順~解析まで, 2010.8.17
19) Akamatsu G et al:New standards for phantom image quality and SUV harmonization range for multicenter oncology PET studies. Ann Nucl Med 36(2):144-61, 2022
20) Satoh Y et al:Reduction of the fluorine-18-labeled fluorodeoxyglucose dose for clinically dedicated breast positron emission tomography. EJNMMI Phys 6(1):21, 2019
21) Ulaner GA et al:Head-to-head evaluation of 18F-FES and 18F-FDG PET/CT in metastatic invasive lobular breast cancer. J Nucl Med 62(3):326-331, 2020 Available from:http://dx.doi.org/10.2967/jnumed.120.247882
22) Ulaner GA et al:Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology 296(2):370-378, 2020
P.49 掲載の参考文献
1) 日本乳癌検診学会編:乳房MRI検査マニュアル, 金原出版, 2020
2) Noritsugu Takahama et al:Current status of MRI-guided vacuum-assisted breast biopsy in Japan. Breast Cancer 28(6):1188-1194, 2021
3) 何森亜由美:誰も教えてくれなかった乳腺エコー. 医学書院, 2014
4) Ayumi Izumori et al:Usefulness of secondlook ultrasonography using anatomical breast structures as indicators for magnetic resonance imaging-detected breast abnormalities. Breast Cancer 27(1):129-139, 2020
5) Murakami W et al:The clinical impact of MRI screening for BRCA mutation carriers:The first report in Japan. Breast Cancer 26(5):552-561, 2019
6) Spick C et al:Diagnostic utility of secondlook US for breast lesions identified at MR imaging:systematic review and metaanalysis. Radiology 273(2):401-409, 2014
7) Hideo Nakajima et al:Anatomical study of subcutaneous adipofascal tissue:a concept of the protectice adipofascial system(PAFS) and lubricant adipofascial system(LAFS). Scand J Plast Reconstr Surg Hand Surg 38(5):261-266, 2004
8) 何森亜由美:乳管走行のバリエーション. 臨床雑誌外科 80(5):416-422, 2018
P.53 掲載の参考文献
1) Ichizawa N et al:Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women:validation of the UICC T1 subgroup classification. Jpn J Clin Oncol 32(3):108-109, 2002
2) 国立研究開発法人国立がん研究センター がん情報サービスより. https://ganjoho.jp/reg_stat/statistics/stat/cancer/14_breast.html.
3) Gail MH:Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100(14):1037-1041, 2008
4) The benefits and harms of breast cancer screening:an independent review. Lancet 380(9855):1778-1786, 2012
5) Suzuki A et al:Age-specific interval breast cancers in Japan:estimation of the proper sensitivity of screening using a populationbased cancer registry. Cancer Sci 99(11):2264-2267, 2008
6) Tice JA et al:Using clinical factors and mammographic breast density to estimate breast cancer risk:development and validation of a new predictive model. Ann Intern Med 148(5):337-347, 2008
7) Poplack SP et al:Digital breast tomosynthesis:initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenol 189(3):616-23, 2007
8) Cavagnetto F et al:'In vivo' average glandular dose evaluation:one-to-one comparison between digital breast tomosynthesis and full-field digital mammography. Radiat Prot Dosimetry 157(1):53-61, 2013
9) Phi XA et al:Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts-a systematic review and meta-analysis. BMC Cancer 18(1):380, 2018
10) Berg WA et al:Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. Jama 307(13):1394-1404, 2012
12) Riedl CC et al:Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33(10):1128-1135, 2015
13) Kuhl CK et al:Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469-8476, 2005
14) Arai M et al:Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer:first report after establishment of HBOC registration system in Japan. J Hum Genet 63(4):447-457, 2018
15) Ha SM et al:Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations. AJR Am J Roentgenol 209(4):920-928, 2017
16) Ide Y et al:Frequency of high-risk hormone receptor-positive breast cancer patients was much higher in Japanese breast cancer patients with germline BRCA1/2 mutations than in sporadic breast cancer patients. Breast J 27(2):188-190, 2021
17) Warner E et al:Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. Jama 292(11):1317-1325, 2004
18) Kemp Jacobsen K et al:Comparing sensitivity and specificity of screening mammography in the United States and Denmark. Int J Cancer 137(9):2198-2207, 2015
19) Tozaki M et al:Current status of breast cancer screening in high-risk women in Japan. Breast Cancer 28(6):1181-1187, 2021
20) Daly MB et al:Genetic/Familial High-Risk Assessment:Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(1):77-102, 2021
21) 日本乳癌学会:疫学・診断編. 日本乳癌学会:乳癌診療ガイドライン 2, 金原出版, 304, 2018
22) Familial breast cancer:collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101,986 women without the disease. Lancet. 358(9291):1389-1399, 2001
23) Yala A et al:Optimizing risk-based breast cancer screening policies with reinforcement learning. Nat Med 28(1):136-143, 2022
24) 桑山 隆:画像診断技術の動向と臨床応用 BRCA 遺伝子変異陽性患者における乳がんの画像診断, Women's Imaging 2019 Breast Imaging (Vol.14) Precision Medicine時代におけるライフステージと乳がん画像診断. 34(8):62-64, INNERVISION, 2019
P.61 掲載の参考文献
1) Schmid P et al:Pembrolizumab for Early Triple-Negative Breast Cancer. The New England journal of medicine 382:810-21, 2020
2) Untch M et al:Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer(GeparSepto-GBG 69):a randomised, phase 3 trial. The Lancet Oncology 17:345-56, 2016
3) Daveau C et al:Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy? International journal of radiation oncology, biology, physics 79:1452-9, 2011
4) Ring A et al:Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? Journal of clinical oncology 21:4540-5, 2003
5) Early Breast Cancer Trialists' Collaborative Group:Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer:meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology 19:27-39, 2018
6) Peintinger F et al:Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Annals of surgical oncology 13:1443-9, 2006
7) Gharzai LA et al:A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006). Breast cancer research and treatment 187:777-84, 2021
8) Schaefgen B et al:Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? Annals of surgical oncology 23:789-95, 2016
9) Marinovich ML et al:Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. Journal of the National Cancer Institute 105:321-33, 2013
10) Tasoulis MK et al:Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA surgery 155:e204103, 2020
11) Pfob A et al:Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. Journal of clinical oncology JCO2102439, 2022
12) von Minckwitz G et al:Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England journal of medicine 380:617-28, 2019
13) Masuda N et al:Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England journal of medicine 376:2147-59, 2017
P.64 掲載の参考文献
1) Dialani V et al:Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol 22(5):1416-1424, 2015
2) Slanetz PJ et al:ACR Appropriateness Criteria(R) Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. J Am Coll Radiol 14(11S):S462-S475, 2017
3) Cheng Q et al:The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer:A Meta-Analysis. Front Oncol 10:93, 2020
4) McLaughlin R et al:MRI in breast cancer therapy monitoring. NMR Biomed 24(6):712-720, 2011
5) Marinovich ML et al:Early prediction of pathologic response to neoadjuvant therapy in breast cancer:systematic review of the accuracy of MRI. Breast 21(5):669-677, 2012
6) Early Breast Cancer Trialists' Collaborative Group:Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer:meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27-39:2018
7) 山口 倫:乳癌サブタイプと乳腺病理. アトムス 2019

【連載】

P.116 掲載の参考文献
Susumu Eguchi, MD, PhD, FACS Novel Computer-Aided Diagnosis Software December 2021-Volume 233-Issue 6-p686-696doi:10.1016/j-jamcollsurg. 2021. 08.689

最近チェックした商品履歴

Loading...